Fabiana Napolitano

Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Breast Cancer Cells

Endoplasmic Reticulum

Top Venues

Nature communications

NPJ breast cancer

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

James Zhu, Yunguan Wang, Woo Yong Chang, Alicia Malewska, Fabiana Napolitano, Jeffrey C Gahan, Nisha Unni, Min Zhao, Rongqing Yuan, Fangjiang Wu, Lauren Yue, Lei Guo, Zhuo Zhao, Danny Z Chen, Raquibul Hannan, Siyuan Zhang, Guanghua Xiao, Ping Mu, Ariella B Hanker, Douglas Strand, Carlos L Arteaga, Neil Desai, Xinlei Wang, Yang Xie, Tao Wang
Mapping cellular interactions from spatially resolved transcriptomics data. Nature methods (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Fabrizio Di Costanzo, Fabiana Napolitano, Fabio Salomone, Anna Rita Amato, Gennaro Alberico, Fortuna Migliaccio, Giovanna Pecoraro, Annachiara Marra, Felice Crocetto, Antonio Ruffo, Sarah Scagliarini, Sabrina Rossetti, Livio Puglia, Marilena Di Napoli, Roberto Bianco, Alberto Servetto, Luigi Formisano
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors. Cancers 15 (23) (2023)
Stefania Belli, Daniela Esposito, Alessandra Allotta, Alberto Servetto, Paola Ciciola, Ada Pesapane, Claudia M Ascione, Fabiana Napolitano, Concetta Di Mauro, Elena Vigliar, Antonino Iaccarino, Carmine De Angelis, Roberto Bianco, Luigi Formisano
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. NPJ breast cancer 9 (1) (2023)
Stefania Belli, Ada Pesapane, Alberto Servetto, Daniela Esposito, Fabiana Napolitano, Claudia Maria Ascione, Alessandra Allotta, Nicola Zambrano, Federica Zito Marino, Renato Franco, Teresa Troiani, Luigi Formisano, Roberto Bianco
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer. British journal of cancer (2023)
Roberto Buonaiuto, Fabiana Napolitano, Sara Parola, Pietro De Placido, Valeria Forestieri, Giovanna Pecoraro, Alberto Servetto, Luigi Formisano, Pietro Formisano, Mario Giuliano, Grazia Arpino, Sabino De Placido, Carmine De Angelis
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer. Biomolecules 12 (10) (2022)
Francesca Gado, Rebecca Ferrisi, Sarah Di Somma, Fabiana Napolitano, Kawthar A Mohamed, Lesley A Stevenson, Simona Rapposelli, Giuseppe Saccomanni, Giuseppe Portella, Roger G Pertwee, Robert B Laprairie, Anna Maria Malfitano, Clementina Manera
Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells. Molecules (Basel, Switzerland) 27 (9) (2022)
Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Eleonora Mozzillo, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Cancers 13 (19) (2021)
Antonio Santaniello, Fabiana Napolitano, Alberto Servetto, Pietro De Placido, Nicola Silvestris, Cataldo Bianco, Luigi Formisano, Roberto Bianco
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers 11 (10) (2019)